MitraGen is a medical device company specializing in the development and commercialization of transcatheter mitral valve repair technologies. These technologies enable interventional cardiologists to repair the mitral valve without the need for open heart surgery, offering a minimally invasive alternative for the treatment of functional mitral regurgitation (FMR) and congestive heart failure (CHF). By utilizing these innovative technologies, MitraGen aims to improve patient outcomes and provide a more efficient and accessible solution for the treatment of mitral regurgitation.